FDA approve guselkumab for use in active psoriatic arthritis

Approval of this IL-23 inhibitor was based on the results of the DISCOVER-1 and DISCOVER-2 trials. It is currently licensed for use in the UK for moderate to severe plaque psoriasis. It was filed for regulatory review in the EU for psoriatic arthritis in October 2019.


Biospace Inc.